{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:38:51Z","timestamp":1779320331496,"version":"3.51.4"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,7,24]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is a promising experimental immunotherapy that has shown high objective responses in patients with melanoma. Current protocols use a lymphodepletive chemotherapy before infusion of ex vivo expanded TILs, followed by high-dose interleukin-2 (IL-2). Treatment-related toxicities are mainly attributable to the chemotherapy regimen and to the high-dose IL-2 and are generally reversible. Neurological side effects have rarely been described. Nevertheless, due to improvements in cell production techniques and due to combinations with other immunomodulating molecules, side effects not previously described may be encountered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>We report the case of a 53-year-old heavily pretreated patient with melanoma who developed Guillain-Barr\u00e9 syndrome (GBS) 19 days after ACT using autologous TILs, given in the context of a phase I trial. He presented with dorsal back pain, unsteady gait and numbness in hands and feet. Lumbar puncture showed albuminocytological dissociation, and nerve conduction studies revealed prolonged distal motor latencies in median, ulnar, tibial and peroneal nerves, compatible with a GBS. The patient was treated with intravenous immunoglobulins and intensive neurological rehabilitation, with progressive and full recovery at 21 months post-TIL-ACT. Concomitant to the onset of GBS, a cytomegalovirus reactivation on immunosuppression was detected and considered as the most plausible cause of this neurological side effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We describe for the first time a case of GBS occurring shortly after TIL-ACT for melanoma, even though we could not identify with certainty the triggering agent. The report of such rare cases is of extreme importance to build on the knowledge of immune cellular therapies and their specific spectrum of toxicities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001155","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T02:31:52Z","timestamp":1598495512000},"page":"e001155","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Guillain-Barr\u00e9 syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes"],"prefix":"10.1136","volume":"8","author":[{"given":"Angela","family":"Orcurto","sequence":"first","affiliation":[{"name":"Immuno-oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hottinger","sequence":"additional","affiliation":[{"name":"Oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"},{"name":"Service of Neurology, Department of Clinical Neurosciences, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benita","family":"Wolf","sequence":"additional","affiliation":[{"name":"Oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Navarro Rodrigo","sequence":"additional","affiliation":[{"name":"Immuno-oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"},{"name":"Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ochoa de Olza","sequence":"additional","affiliation":[{"name":"Immuno-oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"},{"name":"Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymeric","family":"Auger","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Vaud, Switzerland"},{"name":"Center of Experimental Therapeutics, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Kuntzer","sequence":"additional","affiliation":[{"name":"Service of Neurology, Department of Clinical Neurosciences, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-1498","authenticated-orcid":false,"given":"Denis","family":"Comte","sequence":"additional","affiliation":[{"name":"Service of Immunology and Allergy, Department of Medicine, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Center of Experimental Therapeutics, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gannon","sequence":"additional","affiliation":[{"name":"Center of Experimental Therapeutics, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Kandalaft","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Vaud, Switzerland"},{"name":"Center of Experimental Therapeutics, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[{"name":"Oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Immuno-oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Harari","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Vaud, Switzerland"},{"name":"Center of Experimental Therapeutics, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Trueb","sequence":"additional","affiliation":[{"name":"Immuno-oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Coukos","sequence":"additional","affiliation":[{"name":"Immuno-oncology Service, Department of Oncology, CHUV, Lausanne, Vaud, Switzerland"},{"name":"Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Vaud, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2025100312474731000_8.2.e001155.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"2025100312474731000_8.2.e001155.2","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100312474731000_8.2.e001155.3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40264-018-0779-3","article-title":"Safety and tolerability of adoptive cell therapy in cancer","volume":"42","author":"Wolf","year":"2019","journal-title":"Drug Saf"},{"key":"2025100312474731000_8.2.e001155.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379"},{"key":"2025100312474731000_8.2.e001155.5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081986","article-title":"Clinically relevant immune responses against cytomegalovirus: implications for precision medicine","volume":"20","author":"L\u00e9rias","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025100312474731000_8.2.e001155.6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0759-x"},{"key":"2025100312474731000_8.2.e001155.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"2025100312474731000_8.2.e001155.8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"2025100312474731000_8.2.e001155.9","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(93)90324-R"},{"key":"2025100312474731000_8.2.e001155.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.05.001"},{"key":"2025100312474731000_8.2.e001155.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.123943"},{"key":"2025100312474731000_8.2.e001155.12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir074"},{"key":"2025100312474731000_8.2.e001155.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1110"},{"key":"2025100312474731000_8.2.e001155.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit512"},{"key":"2025100312474731000_8.2.e001155.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.10.010"},{"key":"2025100312474731000_8.2.e001155.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.3.668"},{"key":"2025100312474731000_8.2.e001155.17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/00007890-200105150-00023","article-title":"Guillain-Barr\u00e9 syndrome after solid organ transplantation","volume":"71","author":"El-Sabrout","year":"2001","journal-title":"Transplantation"},{"key":"2025100312474731000_8.2.e001155.18","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13021","article-title":"Guillain-Barr\u00e9 syndrome post renal transplant: a systematic review","volume":"21","author":"Ostman","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2025100312474731000_8.2.e001155.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"2025100312474731000_8.2.e001155.20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.1986.4.1.74","article-title":"Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity","volume":"4","author":"Warrell","year":"1986","journal-title":"J Clin Oncol"},{"key":"2025100312474731000_8.2.e001155.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"2025100312474731000_8.2.e001155.22","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200107000-00004"},{"key":"2025100312474731000_8.2.e001155.23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0155-8"},{"key":"2025100312474731000_8.2.e001155.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg207"},{"key":"2025100312474731000_8.2.e001155.25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:47:54Z","timestamp":1759520874000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,26]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jitc-2020-001155"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001155","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}